sponsored
PatientsVille.com Logo

PatientsVille

Commercial Medical Research Studies

Up-to-date List of Commercial Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Commercial Medical Research Studies

Rank Status Study
1 Recruiting Skin Prick Test for the Diagnosis of Food Allergy- a Comparison of Different Commercial Extracts and Raw Food
Condition: Food Allergy
Intervention: Procedure: skin test
Outcome Measure: correlation between the results of skin test with Commercial extracts and raw food
2 Recruiting Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults
Condition: Influenza
Interventions: Biological: Trivalent virosomal influenza vaccine;   Biological: Commercial vaccine 1;   Biological: Quadrivalent virosomal influenza vaccine;   Biological: Commercial vaccine 2
Outcome Measures: Number of participants with Solicited Local Adverse Events (AEs);   Number of participants with Solicited Systemic Adverse Events (AEs);   Number of participants with Unsolicited Adverse Events (AEs);   Number of participants with Serious Adverse Events (SAEs);   Number of Participants with Seroconversion;   Number of Participants with Seroprotection;   Change From Baseline in Geometric Mean Titer (GMT) of HI antibodies
3 Not yet recruiting Study to Estimate the Relative Bioavailability Compared to Commercial Extended-release Tablet Formulation and the Effects of Food Or Sprinkling on Applesauce for Fesoterodine Sustained-release Beads-in-capsule Formulations in Healthy Adult Volunteers
Condition: Healthy
Interventions: Drug: Fesoterodine ER (fasted);   Drug: Fesoterodine SR3 (fasted);   Drug: Fesoterodine SR3 (fed);   Drug: Fesoterodine SR3 (sprinkle);   Drug: Fesoterodine SR4 (fasted);   Drug: Fesoterodine SR4 (fed);   Drug: Fesoterodine SR4 (sprinkle)
Outcome Measures: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)];   Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Plasma Decay Half-Life (t1/2)
4 Recruiting The Effect of Watching a Television Show on the Liking of Snack Foods
Condition: Measure the Grams and Kilocalories of Snack Foods Consumed in Each Condition.
Interventions: Other: Healthy Foods;   Other: Unhealthy Snack Foods
Outcome Measures: Total grams of snack foods consumed;   Measured kilocalories consumed
5 Recruiting Glycemic Index of Mango and Pear in Different Solid Products and Drinks
Condition: Glycemic Index
Interventions: Other: Mango puree and pear juice beverage;   Other: Commercial mango juice;   Other: Fresh natural mango;   Other: Frozen natural mango;   Other: Processed natural mango pulp;   Other: Mix of natural mango and pear;   Other: 50 grams glucose load
Outcome Measures: Glycemic index of mango puree with natural pear juice beverage;   Glycemic index of a Commercial mango juice;   Glycemic index of natural fresh mango;   Glycemic index of natural frozen mango pulp;   Glycemic index of processed natural mango pulp;   glycemic index of a mixture of fresh mango 73 percent and fresh pear 27 percent;   glycemic index of a 50 gram glucose load
6 Recruiting My Lifestyle Intervention of Food and Exercise
Condition: Breast Cancer
Interventions: Behavioral: Tailored Lifestyle Intervention (TLI);   Behavioral: Commercial Weight Loss Program (CWLP)
Outcome Measures: Change in body weight from baseline to post-intervention;   Change in body weight from post-intervention to follow-up;   Change in inflammatory/metabolic disease markers associated with breast cancer recurrence from baseline to post-intervention;   Change in HDL Cholesterol from baseline to post-intervention;   Change in blood glucose control from baseline to post-intervention.;   Change in caloric intake from baseline to post-intervention.;   Change in body composition from baseline to post-intervention.;   Change in waist circumference from baseline to post-intervention.;   Change in sagittal abdominal diameter from baseline to post-intervention.;   Change in physical activity from baseline to post-intervention.;   Change in health-related quality of life from baseline to post-intervention.;   Change in self-efficacy from baseline to post-intervention.;   Use of weight management strategies;   Height;   Change in blood pressure from baseline to post-intervention.;   Change in LDL cholesterol at from baseline to post-intervention.;   Change in total cholesterol from baseline to post-intervention.;   Change in triglycerides from baseline to post-intervention.;   Change in inflammatory/metabolic disease markers associated with breast cancer recurrence from post-intervention to follow-up.;   Change in HDL Cholesterol from post-intervention to follow-up.;   Change in blood glucose control from post-intervention to follow-up.;   Change in caloric intake from post-intervention to follow-up.;   Change in body composition from post-intervention to follow-up.;   Change in waist circumference from post-intervention to follow-up.;   Change in sagittal abdominal diameter from post-intervention to follow-up.;   Change in physical activity from post-intervention to follow-up.;   Change in health-related quality of life from post-intervention to follow-up.;   Change in self-efficacy from post-intervention to follow-up.;   Use of weight management strategies at follow-up.;   Change in blood pressure from post-intervention to follow-up.;   Change in LDL cholesterol at from post-intervention follow-up;   Change in total cholesterol from post-intervention to follow-up.;   Change in triglycerides from post-intervention to follow-up.
7 Recruiting Effect of Feed Warming Method on Feeding Tolerance in the Preterm Infant Born at Less Than 30 Weeks Gestation
Condition: Enteral Feeding
Intervention: Other: Feedings warmed with Commercial warmer
Outcome Measures: Feeding intolerance;   Full enteral feeding
8 Recruiting FastFES Gait Training for Stroke Patients: Efficacy of Pre-Commercial Device
Conditions: Stroke;   Gait
Intervention: Device: FastFES
Outcome Measure: Change from baseline in "6-minute Walk Test (6MWT) for Distance" at 12 weeks
9 Recruiting Growth and Plasma Amino Acids in Infants With CMPA and Treated With a Newly Innovated Amino Acid Formula
Condition: Cow Milk Allergy
Intervention: Dietary Supplement: Comparison of treatment with different amino acid formulas
Outcome Measures: Growth and protein status;   Growth
10 Recruiting A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects
Condition: Infections, Bacterial
Interventions: Drug: GSK1322322 Initial fit for purpose tablets;   Drug: GSK1322322 over granulated tablets;   Drug: GSK1322322 intended Commercial tablets;   Drug: Placebo tablets;   Drug: 13C-GSK1322322 stable isotope powder;   Drug: GSK1322322 for injection;   Drug: Placebo injection
Outcome Measures: Composite of PK parameters for single oral dose of GSK1322322 in Part A;   AUC(0-infinite) comparison for bioavailability assessment for three formulations of GSK1322322 in Part A;   Composite of PK parameters to assess dose proportionality of the GSK1322322 Over-granulated formulation tablets of 1500 mg and 2000 mg;   Composite of PK parameters for single oral dose of GSK1322322 in healthy Japanese subjects in Part B;   Composite of PK parameters for single intravenous (IV) dose of GSK1322322 in healthy Japanese subjects in Part B;   Composite of PK parameters for repeat IV dose of GSK1322322 in healthy Japanese subjects in Part C;   Safety and tolerability of single oral dose of GSK1322322 in healthy subjects assessed by the collection of adverse events (AEs) in Part A;   Collection of AEs to assess safety and tolerability of single oral and IV GSK1322322 doses in healthy Japanese male subjects in Part B;   Collection of AEs to assess safety and tolerability of repeat oral and IV GSK1322322 doses in healthy Japanese male Subjects in Part C;   Safety as assessed by hematology, clinical chemistry, urinalysis, vital signs, electrocardiogram (ECG) intervals, ECG rhythm in healthy subjects in Part A;   Safety as assessed by hematology, clinical chemistry, urinalysis, vital signs, ECG intervals, ECG rhythm in healthy Japanese male Subjects in Part B;   Safety as assessed by hematology, clinical chemistry, urinalysis, vital signs, ECG intervals, ECG rhythm in healthy Japanese male Subject in Part C;   Dose proportionality of GSK1322322 following IV and oral single dose in Part B;   GSK1322322 accumulation ratio following repeat IV administration in Part C;   The potential relationship of CL/CLss following single IV dose versus body weight in Part B;   The potential relationship of CL/CLss following repeat IV doses versus body weight in Part C
11 Recruiting Ultrasound-guided Blood Sampling With a Sterile and Dry Puncture Area
Conditions: Ultrasound;   Sterile Puncture Area;   Blood Sampling
Intervention: Device: A product type of the modified Commercial drape Tegaderm (R)
Outcome Measures: Number of successful blood withdrawals;   Image quality with and without sterile cover
12 Unknown  Bioequivalence Of A Test Alprazolam Sublingual Formulation Compared To A Commercial Sublingual Formulation
Condition: Healthy
Interventions: Drug: alprazolam sublingual tablet Commercial;   Drug: alprazolam sublingual tablet test
Outcome Measures: Alprazolam bioavailability assessed as area under the concentration-time curve (AUC) and maximum concentration (Cmax);   Alprazolam time of maximum concentration (Tmax) and half life;   Adverse events, clinical laboratory tests, vital signs
13 Recruiting Comparison of Different Oral Rehydration Solutions
Condition: Short Bowel Syndrome
Interventions: Dietary Supplement: WHO ORS;   Dietary Supplement: Commercial ORS
Outcome Measures: Number of patients who will regularly take Oral Rehydration Solution (ORS) when the newly available ORS is compared to the World Health Organisation ORS.;   Changes in the electrolytes in subjects using the Commercial ORS versus the WHO ORS
14 Not yet recruiting A Toolbox Approach to Obesity Treatment in Primary Care
Condition: Obesity With Co-morbid Conditions
Interventions: Behavioral: Commercial weight loss program;   Behavioral: Colorado Weigh;   Dietary Supplement: Meal replacements;   Drug: Pharmacotherapy for obesity;   Behavioral: Recrecation center passes
Outcome Measures: Weight change;   Health care utilization;   Documentation of obesity
15 Recruiting Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed State
Condition: Urologic Diseases
Interventions: Drug: Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;   Drug: Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
Outcome Measures: Pharmacokinetic profile for second generation dutasteride when co-administered with tamsulosin HCL relative to the currently available Commercial combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg in the fed state to investigate bioequivalence;   Composite of PK parameters for tamsulosin HCL when it is co-adminstered with second generation dutasteride relative to the currently available Commercial dutasteride 0.5 mg and tamsulosin HCL 0.4 mg in the fed state to investigate bioequivalence;   PK profile of dutasteride;   PK profile of tamsulosin HCL;   Clinically significant changes in Vital signs measurements to assess safety and tolerability;   Incidence of adverse events (AEs);   Clinical laboratory parameter assessment as a measure of safety and tolerability
16 Recruiting Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted State
Condition: Urologic Diseases
Interventions: Drug: Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;   Drug: Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
Outcome Measures: Pharmacokinetic (PK) profile of second generation dutasteride when co-administered with tamsulosin HCL relative to the Commercial combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg in the fed state to investigate bioequivalence;   Composite of PK parameters for tamsulosin HCl when it is co-administered with second generation dutasteride relative to the currently available Commercial dutasteride 0.5 mg + tamsulosin HCL 0.4 mg in the fed state to investigate bioequivalence;   PK profile of dutasteride;   PK profile of tamsulosin HCl;   Clinically significant changes in Vital signs measurements to assess safety and tolerability;   Incidence of adverse events (AEs);   Clinical laboratory parameter assessment as a measure of safety and tolerability
17 Recruiting XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study
Conditions: Angioplasty;   Cardiovascular Disease;   Chronic Coronary Occlusion;   Coronary Artery Bypass Graft (CABG);   Coronary Artery Disease;   Coronary Heart Disease;   Coronary Restenosis;   Myocardial Infarction;   Myocardial Ischemia;   Stent Thrombosis;   Vascular Disease
Intervention: Device: XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
Outcome Measures: Composite rate of cardiac death and all myocardial infarction (MI) (Q-wave and non-Qwave);   Composite rate of all death and all myocardial infarction (MI) (Q-wave and non-Q-wave);   Target lesion failure (TLF): the composite rate of cardiac death, target vessel MI (TVMI), and ischemia-driven target lesion revascularization (ID-TLR);   Target vessel failure (TVF): the composite rate of cardiac death, all MI, and ischemiadriven target vessel revascularization (ID-TVR);   Stent thrombosis (definite and probable, per Academic Research Consortium[ARC] definition);   Death (cardiac, vascular, and non-cardiovascular);   All MI (including Q-wave and non-Q-wave);   Revascularization (target lesion, target vessel, and non-target vessel) (PCI and Coronary Artery Bypass Graft [CABG])
18 Unknown  A Study Designed to Compare 2 Formulations of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Technosphere Insulin A;   Drug: Technosphere Insulin B;   Drug: Humalog
Outcome Measures: Insulin AUC0-360min for TIB and TIA (assessment of bioequivalence) Insulin AUC0-360min for TIB to RAA (assessment of relative bioavailability);   Additional PK parameters of serum insulin and FDKP
19 Recruiting Glue Application in the Treatment of Low-Output Fistulas
Condition: Low-output External Gastrointestinal Fistula
Interventions: Procedure: Endoscopy exploration and glue application;   Procedure: Endoscopy exploration;   Drug: Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin);   Dietary Supplement: Nutrition support
Outcome Measures: Closure rates up to 14 days;   Number of adverse events
20 Recruiting Italian Platelet Technology Assessment Study
Conditions: Leukemia;   Lymphoma
Intervention: Procedure: Platelet transfusion
Outcome Measures: Incidence of bleeding of grade 2 or greater in recipients of PRT platelets versus incidence in recipients of control (standard) platelets;   Time to the first grade 2 or greater bleeding event after the first study transfusion;   Proportion of transfusions given to treat breakthrough bleeding;   Number of days with grade 2 or greater bleeding during the period of platelet transfusion support;   Number of platelet units transfused per day of thrombocytopenic platelet support;   Proportion of patients with acute transfusion reactions;   Post-transfusion platelet count increments;   Total dose of platelets transfused per day of thrombocytopenic platelet support

These studies may lead to new treatments and are adding insight into Commercial etiology and treatment.

A major focus of Commercial research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Commercial